ERBB2 and adenocarcinoma: A total of 383 patients (64%; 90% in adenocarcinomas and 19% in other NSCLCs) were tested for genetic alterations with NGS and of these 35 (9%) had the KRAS G12C mutation, 74 (19%) other KRAS mutation (Gly12Val; n = 28, Gly12Asp; n = 15, Gly12Ala; n = 11, Gly61His; n = 8, Gly12Ser; n < 5, Gly13Cys; n < 5, Gly12Arg; n < 5, Ala146Thr; n < 5, Gln61Leu; n < 5, Gln61Lys; n < 5, Gly12Phe; n < 5, Gly13Asp; n < 5), 68 (18%) other driver mutation (BRAF; n = 14, EGFR; n = 40, MET or HER2; n = 14), and 206 (54%) did not have any driver mutations detected.